Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam)
Authors:
Open Access
- 20 August 1999
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 84 (4) , 437-441
Abstract
A randomized screening trial was started in Europe to show the effect of early detection and treatment of prostate cancer on mortality (European Study on Screening of Prostate Cancer). In one centre (Rotterdam), the screening protocol initially consisted of 3 screening tests for all men: prostate‐specific antigen (PSA), digital rectal examination (DRE) and transrectal ultrasonography (TRUS). A PSA value of ≥4 ng/ml and/or an abnormality on DRE and/or TRUS were taken to indicate that biopsy was required. In this study, we examined the possibilities for a more efficient screening protocol. A logistic‐regression model was used to predict the number of cancers for PSA < 4 ng/ml if all men were biopsied (predictive index, PI). Effects of a change in PSA cut‐off on the screening results were explored. Weights were applied to procedures and cancers to explore the possibility of expressing differences between protocols in one overall figure. Biopsies in men with PSA < 1 ng/ml and a positive DRE or TRUS were very inefficient. Applying DRE and TRUS only in the PSA ranges 1.5 to 3.9 and 2 to 3.9 ng/ml to determine whether a biopsy was required would result in a decrease of 29 to 36% in biopsies and a decrease of 5 to 8% in cancers. However, the results of DRE and TRUS could not be duplicated entirely. A protocol with only PSA ≥ 3 ng/ml as a direct biopsy indicator resulted in a decrease of detected cancers by 7.6% and of biopsies by 12%, also a much simpler screening procedure. Use of the PI would give more efficient protocols, but this should be viewed as a preliminary finding, with the disadvantage of necessitating many additional screening visits. Since the results of DRE and TRUS could not be duplicated, a change in protocol towards PSA ≥ 3 ng/ml appears acceptable. If this proves effective, a final judgement about the optimal combination of screening tests may be made. Int. J. Cancer (Pred. Oncol.) 84:437–441, 1999.Keywords
This publication has 12 references indexed in Scilit:
- Short-Term Effects of Population-Based Screening for Prostate Cancer on Health-Related Quality of LifeJNCI: Journal of the National Cancer Institute, 1998
- CHARACTERISTICS OF SCREENING DETECTED PROSTATE CANCER IN MEN 50 TO 66 YEARS OLD WITH 3 TO 4 NG./ML. PROSTATE SPECIFIC ANTIGENJournal of Urology, 1998
- Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening programUrology, 1997
- Prostate Cancer Detection in Men With Serum PSA Concentrations of 2.6 to 4.0 ng/mL and Benign Prostate ExaminationJAMA, 1997
- Prospective Evaluation Plan for Randomised Trials of Prostate Cancer ScreeningJournal of Medical Screening, 1996
- European randomized study of screening for prostate cancer—The Rotterdam pilot studiesInternational Journal of Cancer, 1996
- Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancerBMJ, 1995
- European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam Pilot studiesCancer, 1995
- A Screening Study of Prostate Cancer in High Risk FamiliesJournal of Urology, 1992
- Breast cancer screening and cost‐effectiveness; Policy alternatives, quality of life considerations and the possible impact of uncertain factorsInternational Journal of Cancer, 1991